Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

OBJECTIVE: Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Hida, Toyoaki, Atagi, Shinji, Sakai, Hiroshi, Nakagawa, Kazuhiko, Takahashi, Toshiaki, Nogami, Naoyuki, Saka, Hideo, Takenoyama, Mitsuhiro, Maemondo, Makoto, Ohe, Yuichiro, Nokihara, Hiroshi, Hirashima, Tomonori, Tanaka, Hiroshi, Fujita, Shiro, Takeda, Koji, Goto, Koichi, Satouchi, Miyako, Isobe, Hiroshi, Minato, Koichi, Sumiyoshi, Naoki, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
ESMO Asia paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566979/
https://www.ncbi.nlm.nih.gov/pubmed/28861280
http://dx.doi.org/10.1136/esmoopen-2016-000108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566979/
https://www.ncbi.nlm.nih.gov/pubmed/28861280
http://dx.doi.org/10.1136/esmoopen-2016-000108

Ejemplares similares